Targeting of protease activator receptor-2 (PAR-2) antagonist FSLLRY-NH2 as an asthma adjuvant therapy

por Ocasio-Rivera, Marinel, Marin-Maldonado, Frances, Trossi-Torres, Geraline, Ortiz-Rosado, Angely, Rodríguez-Irizarry, Valerie, Rodriguez-Lopez, Eric, Martínez, Sahayra, Almodóvar, Sharilyn, Suarez-Martínez, Edu
Publicado 2020

Genetic targeting of Card19 is linked to disrupted NINJ1 expression, impaired cell lysis, and increased susceptibility to Yersinia infection

por Bjanes, Elisabet, Sillas, Reyna Garcia, Matsuda, Rina, Demarco, Benjamin, Fettrelet, Timothée, DeLaney, Alexandra A., Kornfeld, Opher S., Lee, Bettina L., Rodríguez López, Eric M., Grubaugh, Daniel, Wynosky-Dolfi, Meghan A., Philip, Naomi H., Krespan, Elise, Tovar, Dorothy, Joannas, Leonel, Beiting, Daniel P., Henao-Mejia, Jorge, Schaefer, Brian C., Chen, Kaiwen W., Broz, Petr, Brodsky, Igor E.
Publicado 2021